单独夹板、单独类固醇注射与两者联合治疗成人扳机指在疼痛缓解和功能改善方面是否存在差异?
该随机对照试验纳入120例成人扳机指患者,比较单独夹板、单独类固醇注射及两者联合在6、12、52周时的疼痛缓解和功能改善,结果显示三组在VAS疼痛评分和MHQ评分上均无临床重要差异,作者推荐单独夹板作为初始治疗。
要点
- 三组在6、12、52周时VAS疼痛评分和MHQ评分均无临床重要差异。
- 作者推荐单独夹板作为成人扳机指的初始治疗。
- 作者认为类固醇注射联合夹板无优势,因获益与单独治疗无差异。
核心结论
- 作者推荐单独夹板作为成人扳机指的初始治疗,因为单独夹板与单独类固醇注射在长达1年的疼痛缓解和症状或功能改善方面无临床重要差异。
- 作者认为类固醇注射联合夹板无优势,因为其在疼痛缓解和症状或功能改善方面的获益与单独类固醇注射或单独夹板无差异。
研究设计与样本
- 2021年5月至2021年12月在一所大学附属医院治疗165例成人扳机指患者,排除45例后120例随机分配至夹板组(n=43)、类固醇注射组(n=40)或夹板联合类固醇注射组(n=37)。
- 采用计算机生成的区组随机化(区组大小为6),使用序贯编号、不透明、密封信封进行分配隐藏,分配者和结果评估者均设盲。
- 夹板治疗为患者佩戴固定掌指关节中立位矫形器,每天至少8小时,连续6周。
- 类固醇注射为1 mL不含肾上腺素的1%利多卡因与1 mL曲安奈德(10 mg/mL)直接注入屈肌腱鞘。
- 主要结局为干预后6、12、52周时VAS疼痛减轻和密歇根手部结局问卷(MHQ)评分改善,VAS和MHQ的最小临床重要差异(MCID)分别为1和10.9。
主要发现
- 在意向治疗分析和符合方案分析中,三个治疗组在任何时间点的VAS疼痛评分均无临床重要差异。
- 在意向治疗分析和符合方案分析中,三个治疗组在任何时间点的MHQ评分均无临床重要差异。
- 干预后6周或12周无患者失访或治疗失败,52周时各治疗组失访无差异。
- 在意向治疗分析中纳入全部120例患者,符合方案分析在排除失访或治疗失败患者后纳入86例患者。
关键数值与推荐
- VAS疼痛减轻的MCID值为1,MHQ评分改善的MCID值为10.9。
- 类固醇注射使用1 mL 1%利多卡因(不含肾上腺素)和1 mL曲安奈德(10 mg/mL)。
- 夹板治疗为每天至少8小时,连续6周。
临床怎么用
- 作者推荐单独夹板作为成人扳机指的初始治疗。
- 作者认为类固醇注射联合夹板无优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Steroid injection and splinting, which are commonly recommended nonsurgical treatments in adults with trigger finger, have been demonstrated to effectively relieve pain and improve function. However, to our knowledge, there have been no direct comparisons of pain relief and function improvement with splinting alone, steroid injection alone, or a combination of splinting and steroid injection in patients with this diagnosis. QUESTION/PURPOSE: Are there differences in pain reduction and functional improvement in adults with trigger finger treated with splinting alone, steroid injection alone, and a combination of splinting and steroid injection at 6, 12, and 52 weeks after the intervention? METHODS: Between May 2021 and December 2021, we treated 165 adult patients for trigger finger at an academic university hospital. Based on prespecified criteria, all patients we saw during that period were eligible, but 27% (45 of 165) were excluded because they had received a previous local corticosteroid injection (n = 10) or they had concomitant carpal tunnel syndrome (n = 14), first carpometacarpal joint arthritis (n = 3), osteoarthritis of the hand (n = 6), de Quervain disease (n = 3), multiple-digit trigger finger (n = 6), or pregnancy during the study period (n = 3). After screening, 120 patients were randomized to receive either splinting (n = 43), steroid injection (n = 40), or splinting plus steroid injection (n = 37). Patients were randomly assigned to the different treatments using computer-generated block randomization (block of six). Sequentially numbered, opaque, sealed envelopes were used in the allocation concealment process. Both the allocator and the outcome assessor were blinded. Splinting involved the patient wearing a fixed metacarpophalangeal joint orthosis in the neutral position at least 8 hours per day for 6 consecutive weeks. Steroid injection was performed using 1 mL of 1% lidocaine without epinephrine and 1 mL of triamcinolone acetonide (10 mg/mL) injected directly into the flexor tendon sheath. No patients were lost to follow-up or had treatment failure (that is, the patient had persistent pain or triggering with the trigger finger treatment and requested additional medical management including additional splinting, steroid injection, or surgery) at 6 or 12 weeks after the intervention, and at 52 weeks, there was no difference in loss to follow-up among the treatment groups. An intention-to-treat analysis was performed with all 120 patients, and a per-protocol analysis was conducted with 86 patients after excluding patients who were lost to follow-up or had treatment failure. Primary outcomes evaluated were VAS pain reduction and improvement in Michigan Hand Outcomes Questionnaire (MHQ) scores at 6, 12, and 52 weeks after the intervention. The minimum clinically important difference (MCID) values were 1 and 10.9 for the VAS and MHQ, respectively. RESULTS: There were no clinically important differences in VAS pain scores among the three treatment groups at any timepoint, in either the intention-to-treat or the per-protocol analyses. Likewise, there were no clinically important differences in MHQ scores at any timepoint in either the intention-to-treat or the per-protocol analyses. CONCLUSION: Splinting alone is recommended as the initial treatment for adults with trigger finger because there were no clinically important differences between splinting alone and steroid injection alone in terms of pain reduction and symptom or functional improvement up to 1 year. The combination of steroid injection and splinting is disadvantageous because the benefits in terms of pain reduction and symptom or functional improvement are not different from those achieved with steroid injection or splinting alone. LEVEL OF EVIDENCE: Level I, therapeutic study.
引用
- Atthakomol P, Wangtrakunchai V, Chanthana P, et al. Are There Differences in Pain Reduction and Functional Improvement Among Splint Alone, Steroid Alone, and Combination for the Treatment of Adults With Trigger Finger? Clin Orthop Relat Res. 2023. PMID: 37083487. doi:10.1097/CORR.0000000000002662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。